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ABCB5-Targeted Chemoresistance Reversal
Inhibits Merkel Cell Carcinoma Growth
Sonja Kleffel1, Nayoung Lee1, Cecilia Lezcano2, Brian J. Wilson3, Kristine Sobolewski1,
Karim R. Saab3, Hansgeorg Mueller1, Qian Zhan2, Christian Posch1, Christopher P. Elco1,2,
Andrew DoRosario4, Sarah S. Garcia1,4, Manisha Thakuria1,4, Yaoyu E. Wang5,
Linda C. Wang1,4, George F. Murphy2, Markus H. Frank1,3,6 and Tobias Schatton1,3
Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer with profound but poorly
understood resistance to chemotherapy, which poses a significant barrier to clinical MCC treatment. Here we
show that ATP-binding cassette member B5 (ABCB5) confers resistance to standard-of-care MCC chemother-
apeutic agents and provide proof-of-principle that ABCB5 blockade can inhibit human MCC tumor growth
through sensitization to drug-induced cell cytotoxicity. ABCB5 expression was detected in both established
MCC lines and clinical MCC specimens at levels significantly higher than those in normal skin. Carboplatin-
and etoposide-resistant MCC cell lines exhibited increased expression of ABCB5, along with enhanced ABCB1
and ABCC3 transcript expression. ABCB5-expressing MCC cells in heterogeneous cancers preferentially sur-
vived treatment with carboplatin and etoposide in vitro and in human MCC xenograft-bearing mice in vivo.
Moreover, patients with MCC also exhibited enhanced ABCB5 positivity after carboplatin- and etoposide-based
chemotherapy, pointing to clinical significance of this chemoresistance mechanism. Importantly, ABCB5
blockade reversed MCC drug resistance and impaired tumor growth in xenotransplantation models in vivo.
Our results establish ABCB5 as a chemoresistance mechanism in MCC and suggest utility of this molecular
target for improved MCC therapy.
Journal of Investigative Dermatology (2016) 136, 838e846; doi:10.1016/j.jid.2015.12.038
INTRODUCTION
Merkel cell carcinoma (MCC) is a highly aggressive neuroen-
docrine cancer of the skin that, on a case-by-case basis, is
more deadly than melanoma (Poulsen, 2004). Although MCC
is relatively rare, its incidence has tripled over the past two
decades and continues to rise by 8% annually (Hodgson,
2005). Current treatment modalities are local excision sur-
gery of primary lesions and chemo- and radiation therapy
of metastatic disease (Eng et al., 2007). Although combination
therapy with carboplatin and etoposide, the first-line chemo-
therapeutic agents utilized in advanced-stage MCC, yields
initial response rates of up to 60%, most patients experience
disease relapse, usually with fatal outcomes (Tai et al., 2000).
Because of the limited availability of human MCC cell lines
and patient samples from this rare form of cancer (Becker,
2010), mechanisms of MCC chemotherapy resistance are
largely understudied, and treatment of patients with advanced
disease poses a significant challenge. Thus, elucidating the
mechanisms underlying MCC therapeutic resistance is of
critical importance for improving patient survival.
We have previously cloned and characterized ATP-binding
cassette member B5 (ABCB5) (Frank et al., 2003, 2005, 2011;
Ksander et al., 2014; Lin et al., 2013; Schatton et al., 2008,
2010, 2015; Wilson et al., 2011, 2014), which has been
shown to serve as a clinically relevant multidrug resistance
mediator in human malignant melanoma (Chartrain et al.,
2012; Frank et al., 2005; Wilson et al., 2014), colorectal
cancer (Wilson et al., 2011), and hepatocellular carcinoma
(Cheung et al., 2011). Moreover, ABCB5 expression corre-
lates with tumor virulence and clinical cancer progression in
these malignancies (Cheung et al., 2011; Gazzaniga et al.,
2010; Schatton et al., 2008; Setia et al., 2012; Sharma
et al., 2010; Wilson et al., 2011). Given its role in multi-
drug resistance of multiple malignancies, we hypothesized
that ABCB5 might also identify therapy-refractory tumor
populations in MCC.
The herein reported results establish ABCB5 expression
in MCC and show that ABCB5 marks therapy-refractory
tumor subpopulations after standard-of-care carboplatin- and
etoposide-based combination chemotherapy in patients with
MCC. Similarly, inMCCxenotransplantationmodels, ABCB5þ
tumor cells also preferentially survive carboplatin- and
etoposide-induced cytotoxicity.Moreover, antibody-mediated
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ABCB5 blockade sensitizes MCC cells to carboplatin- and
etoposide-mediated cell killing concomitant with significantly
enhanced inhibition of MCC xenograft growth.
RESULTS AND DISCUSSION
In healthy human skin, ABCB5 is expressed only on rare
subsets of cells (Frank et al., 2003; Schatton et al., 2015).
Similarly, in human malignant melanoma, ABCB5 expression
is confined to relatively rare tumorigenic minority pop-
ulations (Schatton et al., 2008). Clinical human MCC speci-
mens obtained at various stages of disease progression
(n ¼ 85), on the other hand, demonstrated marked ABCB5
membrane expression by cytokeratin 20-positive MCC
cells (Figure 1a). Although cell-cell membrane apposition
made it difficult to enumerate numbers of positive cells
and specimens displayed heterogeneity for ABCB5 expres-
sion, ABCB5 immunoreactivity was typically observed
in the majority of tumor cells. Supplementary Table S1
online summarizes the clinical parameters for all MCC bi-
opsy specimens analyzed. Aggregate quantitative reverse
transcription polymerase chain reaction (RT-PCR)-based
analysis of all tissue specimens showed significantly higher (P
< 0.001) ABCB5 mRNA expression in biopsies from patients
with MCC (n ¼ 85) compared with normal human skin (n ¼
10) (Figure 1b). Based on the previously described correlation
of ABCB5 frequency with chemotherapeutic refractoriness in
cancer patients (Chartrain et al., 2012; Cheung et al., 2011;
Wilson et al., 2011), we next examined ABCB5 expression
levels in MCC samples obtained before and after first-line
chemotherapy from three patients afflicted by this
Figure 1. ABCB5 expression in patients with MCC before and after first-line chemotherapy. (a) Representative H&E, CK20, and ABCB5 immunohistochemistry
of a primary MCC tumor, a lymph node and visceral metastasis. (b) Relative ABCB5 mRNA expression in normal human skin (n ¼ 10) versus clinical MCC
specimens (n ¼ 85), as determined by quantitative RT-PCR. (c) Relative ABCB5 mRNA expression and (d) immunohistochemically determined ABCB5 protein
expression (mean  SEM) by patient-matched pre- and post-chemotherapy MCC biospecimens (n ¼ 3, respectively). Size bars ¼ 50 mm. (NS: not significant,
***P < 0.001, as determined by the unpaired (b) or paired (c, d) Student’s t-test). ABCB5, ATP-binding cassette member B5; CK20, cytokeratin 20; H&E,
hematoxylin and eosin; MCC, Merkel cell carcinoma; RT-PCR, reverse transcription polymerase chain reaction; SEM, standard error of the mean.
S Kleffel et al.
ABCB5 and Merkel Cell Carcinoma Resistance
www.jidonline.org 839
Figure 2. ABCB5 expression in response to in vitro carboplatin and etoposide treatment. (a) ABCB5 mRNA expression by MKL-1, MKL-2, MS-1, and WaGa
MCC cell lines, as determined by RT-PCR (positive control: G3361 melanoma cells). (b) Representative ABCB5 immunofluorescence staining (red) of a cytospin
preparation of WaGa cells (inset: isotype control antibody staining). Nuclei are counterstained with 40,6-diamidino-2-phenylindole (blue). Size bars ¼ 50 mm.
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extraordinarily rare orphan disease with availability of this
unique biopsy material. Analysis of patient-matched pre- and
postchemotherapy MCC specimens revealed significantly
increased ABCB5 mRNA expression in postchemotherapy
local recurrences compared with prechemotherapy biopsy
specimens, both at the mRNA (Figure 1c) and immunoreac-
tive protein levels (cell frequency 59.2  4.1% vs. 14.0 
1.0%, mean  standard error of the mean, respectively,
P < 0.001) (Figure 1d). These findings in patient specimens
were consistent with the possibility that ABCB5þ MCC cells
are preferentially resistant to treatment with the first-line
chemotherapeutic agents, carboplatin and etoposide.
On the basis of previous studies implicating ABCB5
expression in conferring chemotherapeutic resistance in
several human cancers (Chartrain et al., 2012; Cheung et al.,
2011; Frank et al., 2005; Wilson et al., 2011, 2014), we next
examined the potential functional contribution of ABCB5 to
carboplatin and/or etoposide resistance in MCC. We first
demonstrated ABCB5 mRNA expression in the established
human MCC cell lines, MKL-1, MKL-2, MS-1, and WaGa
(Guastafierro et al., 2013; Houben et al., 2010; Rodig et al.,
2012; Rosen et al., 1987), by RT-PCR amplification and
sequencing (Figure 2a). All four MCC lines also showed
ABCB5 surface protein expression, as determined by immu-
nofluorescence staining (Figure 2b) and by flow cytometric
analysis, with ABCB5þ cell frequencies (mean  standard
error of the mean) averaging 10.0  1.8% for MKL-1, 9.1 
2.4% for MKL-2, 8.3  1.5% for MS-1, and 16.9  5.4% for
WaGa cells (Figure 2c). To explore the potential role of
ABCB5 in MCC refractoriness to first-line chemotherapy, we
next investigated ABCB5 expression in control (wild-type)
versus MCC lines rendered drug resistant via continuous
exposure to carboplatin or etoposide over a 2-month period.
First, we confirmed preferential survival of carboplatin- and
etoposide-resistant compared with wild-type MCC cells for
the respective drugs (Supplementary Figure S1a online).
Subsequent quantitative RT-PCR analyses revealed markedly
increased ABCB5 mRNA expression levels in both carbo-
platin- and etoposide-resistant MKL-1, MKL-2, MS-1, and
WaGa lines compared with the respective wild-type cell lines
(Figure 2d). At the protein level, exposure to cytotoxic levels
of carboplatin or etoposide resulted in significantly increased
ABCB5 expression among viable MKL-1, MKL-2, MS-1, and
WaGa cells compared with vehicle-treated controls, respec-
tively (Figure 2e and f). Although the percentage of ABCB5þ
cells was markedly enhanced in chemorefractory MCC cell
lines, we also noted that a significant proportion of carbo-
platin- and etoposide-resistant cells did not display ABCB5
expression.
To directly demonstrate that ABCB5þ tumor cell subsets
preferentially survive carboplatin- and etoposide-induced
cytotoxicity, we compared the viability of ABCB5þ versus
ABCB5 MKL-1 and WaGa cells grown in the presence of
cytotoxic carboplatin or etoposide levels. We found that
ABCB5þ cells cultured under these conditions demonstrated
increased viability compared with ABCB5MCC populations
(Figure 2g), indicating that ABCB5þ MCC subsets preferen-
tially survive drug-induced cell killing. However, we cannot
entirely exclude the possibility of induction of ABCB5
expression, as opposed to preferential survival. Because other
ABC transporters, including ABCB1, ABCC3, and ABCG2,
are known mediators of carboplatin and etoposide resistance
in other cancers (Dean et al., 2001), we examined whether
drug-resistant MCC lines also expressed high levels of these
ABC transporters, in addition to ABCB5. With the exception
of etoposide-resistant MKL-1 cells, all drug-resistant MCC
cell lines examined showed a significant increase in ABCB1
and ABCC3, but not ABCG2 transcript expression compared
with the respective wild-type cell lines (Supplementary
Figure S1b), raising the possibility that several ABC trans-
porters, in addition to ABCB5, might contribute to che-
moresistance in drug-induced MCC cell lines. Together,
these results suggested a direct relationship between
therapeutic resistance to both carboplatin and etoposide
treatment and ABCB5 expression in the MCC lines evalu-
ated, and further suggest the potential contribution of
additional ABC transporters (ABCB1 and ABCC3) to MCC
chemoresistance.
To explore the potential role of ABCB5 as a carboplatin
and/or etoposide resistance mediator in MCC, we evaluated
cell viability in MCC cultures exposed to increasing con-
centrations of carboplatin or etoposide in the presence of
an anti-ABCB5 blocking monoclonal antibody (mAb) (Frank
et al., 2003, 2005; Ksander et al., 2014; Schatton et al.,
2008; Wilson et al., 2014) versus isotype control mAb.
ABCB5 blockade reversed carboplatin and etoposide resis-
tance of both MKL-1 and WaGa cells (Figure 3a), resulting
in significantly enhanced cell killing at all carboplatin con-
centrations greater than 1 mM versus controls and at etopo-
side concentrations as low as 10 nM in MKL-1 cells, and
reductions of the LD50 in both MKL-1 (LD50 [carboplatin] 2.3
mM vs. 5.9 mM and LD50 [etoposide] 25.0 nM vs. 62.4 nM,
respectively) and WaGa cells (LD50 [carboplatin] 3.1 mM vs.
7.6 mM and LD50 [etoposide] 98.4 nM vs. 130.4 nM,
respectively) (Figure 3a). Drug-induced selection for ABCB5þ
MCC cells (Figure 2deg) might hereby explain why the
ABCB5 blocking mAb mediates carboplatin- and etoposide-
induced cytotoxicity in proportions of MCC cells that
exceeded those frequencies observed in native cell lines
(Figure 2c), especially at higher drug concentrations. Treat-
ment with the anti-ABCB5 mAb alone had no significant
effect on in vitro cell survival (Figure 3b), but, in line with
(c) Representative flow cytometry of ABCB5 protein expression by MKL-1, MKL-2, MS-1, and WaGa cells (n ¼ 6 independent experiments). (d) Relative ABCB5
mRNA expression (mean  SEM) by MCC cells resistant to 50e150 mM carboplatin or 1e3 mM etoposide compared with that in wild-type MCC cells, as
determined by quantitative RT-PCR (n ¼ 6e9 each, representative of 2e3 independent experiments). (e) Flow cytometrically determined ABCB5 protein
expression (% live cells, mean  SEM) in wild-type versus carboplatin- or etoposide-resistant MCC cells (n ¼ 3e8 independent experiments, respectively).
(f) Representative flow cytometry of ABCB5 protein expression (MKL-1) in experimental groups as in (e) and of (g) cell viability (calcein AM positivity) of wild-
type ABCB5þ versus ABCB5 MCC cells cultured in the presence of cytotoxic carboplatin (250 mM) or etoposide (5 mM) concentrations (*P < 0.05, **P < 0.01,
***P < 0.001, as determined by the unpaired Student’s t-test). ABCB5, ATP-binding cassette member B5; DAPI, 40,6-diamidino-2-phenylindole; MCC, Merkel
cell carcinoma; RT-PCR, reverse transcription polymerase chain reaction; SEM, standard error of the mean.
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blocking specificity, induced compensatory increases in
ABCB5 mRNA expression compared with isotype control
mAb treatment (Figure 3c). To more rigorously demonstrate
that the anti-ABCB5 mAb used in our study blocks ABCB5
function in MCC, we next examined whether it blocked
cellular efflux of the green fluorescent dye and known ABCB5
substrate (Frank et al., 2003; Lin et al., 2013), rhodamine
123 (Rh123) in MCC cells. Compared with isotype control
mAb-treated MCC cells, of which a subpopulation of 19.0 
2.8% (mean  standard error of the mean, n ¼ 3) effluxed
Rh123 over a 120-minute incubation period at 37 C, mAb-
mediated ABCB5 blockade significantly (P < 0.05) inhibited
Rh123 efflux by >60% (Figure 3d). The effect of ABCB5
blockade on Rh123 efflux was assessed compared with
incubation of MCC cells for 120 minutes at 4 C (Figure 3d),
which blocks ATP hydrolysis and hence ABC transport
function (Frank et al., 2003; Lin et al., 2013). Together, these
results established that ABCB5 is expressed as a functional
xenobiotic efflux transporter in MCC, and that ABCB5
blockade reverses carboplatin and etoposide resistance in
this malignancy.
To investigate the relationship betweenABCB5 and first-line
chemotherapy resistance in MCC in vivo, we also examined
ABCB5 expression and carboplatin or etoposide treatment
response of ABCB5þ cancer cell populations in an established
model system (Lezcano et al., 2014) utilizing non-obese dia-
betic/severely combined immunodeficiency IL-2Rg/ (NSG)
mice bearing MKL-1 or WaGa xenografts. MKL-1 and WaGa
tumors grew at similar rates (Supplementary Figure S2a online)
and exhibited cytokeratin 20 and ABCB5 expression profiles
similar to those found in patientMCC samples (Supplementary
Figure S2b). We found that the carboplatin and etoposide
doses (Fichtner et al., 2008) administered to NSG mice for six
consecutive days resulted in significant volume reduction of
preestablished MKL-1 and Wa xenograft tumors, whereas
vehicle-treated controls showed continued tumor growth
Figure 3. Chemoresistance reversal of human MCC cells by ABCB5 inhibition. (a) Effects of anti-ABCB5 versus isotype control antibody on carboplatin- or
etoposide-induced MKL-1 and WaGa cell killing, determined by the MTT assay. Surviving cell fractions are plotted against drug concentration (n ¼ 6 each,
representative of n ¼ 3 independent experiments). (b) Flow cytometric assessment of cell death (percent Annexin-Vþ/7AADþ cells, mean  SEM, n ¼ 3)
and (c) relative ABCB5 mRNA expression (mean  SEM) in isotype control- versus anti-ABCB5 antibody-treated MCC cultures (n ¼ 3e9, respectively).
(d) Representative histogram plot and percent rhodamine 123-effluxing wild-type MKL-1 cells (mean  SEM) under conditions of isotype control or ABCB5-
blocking antibody treatment (37 C), or with incubation at 4 C to block ATP-dependent efflux (n ¼ 3 independent experiments) (NS: not significant, *P < 0.05,
**P < 0.01, ***P < 0.001, as determined by the unpaired Student’s t-test). ABCB5, ATP-binding cassette member B5; MCC, Merkel cell carcinoma; MTT,
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; SEM, standard error of the mean.
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(Figure 4a). Quantitative RT-PCR analysis revealed greater
than eightfold elevation of ABCB5mRNA expression by tumor
xenograft tissue harvested from carboplatin- and etoposide-
treated versus vehicle control-treated MKL-1 (P < 0.001) or
WaGa xenograft-bearing mice (P < 0.05), respectively
(Figure 4b). Compared with tumor xenografts of vehicle
control-treated mice, residual MKL-1 and WaGa specimens
resected fromNSGmice treated with carboplatin or etoposide
also showed 2.0- to 4.3-fold enhanced (P < 0.001, respec-
tively) ABCB5 protein expression by viable MCC cells
(Figure 4c), consistent with our in vitro results (Figure 2). In
line with our in vitro findings, we also found that ABCB1 and
ABCC3 transcript levels tended to be elevated in both MKL-1
and WaGa tumors resected from NSG mice treated with car-
boplatin or etoposide compared with those treated with
vehicle control (Supplementary Figure S3 online).
To determine if ABCB5 blockade in the context of carbo-
platin- or etoposide-based monotherapy has an additive
inhibitory effect on MCC growth in vivo, we administered
submaximal doses of carboplatin (30 mg/kg) or etoposide
(5 mg/kg) in combination with anti-ABCB5 mAb (Frank et al.,
2003, 2005; Ksander et al., 2014; Lin et al., 2013; Schatton
et al., 2008, 2015; Wilson et al., 2014) or isotype control
mAb to MKL-1 or WaGa tumor xenograft-bearing NSG mice.
Compared with the respective vehicle control groups, low-
dose carboplatin or etoposide treatment resulted in signifi-
cantly (P < 0.01) attenuated growth of both MKL-1 and
WaGa tumor xenografts (Figure 5a). Importantly, combina-
tion therapies involving anti-ABCB5 mAb plus carboplatin or
anti-ABCB5 mAb plus etoposide resulted in significantly
greater inhibition of tumor growth compared with treatment
with either chemotherapeutic alone (P < 0.05, respectively)
(Figure 5a). Immunohistochemical analysis of serial sections
of resected MKL-1 and WaGa specimens revealed binding
of in vivo-administered mAb to tumor target tissue, which
coincided with regions of ABCB5 positivity, in anti-ABCB5
mAb-co-treated, but not isotype control mAb-co-treated
carboplatin or etoposide treatment groups (Figure 5b), sup-
porting the notion of a direct anti-ABCB5 mAb effect
on ABCB5þ MCC target cells. Although MKL-1 and
WaGa xenografts of NSG mice treated with either carbo-
platin or etoposide plus isotype control mAb showed only
Figure 4. Response of ABCB5 expression to carboplatin and etoposide treatment in MCC tumor xenografts. (a) Tumor growth kinetics (mean  SD) of
vehicle control-, carboplatin- (75 mg/kg/d) or etoposide-treated (10 mg/kg/d) MKL-1 and WaGa xenografts in NSG mice (n ¼ 6e8, respectively). Arrows
indicate days of carboplatin or etoposide administration. (b) Relative ABCB5 mRNA expression (mean  SEM) determined by quantitative RT-PCR and (c)
immunohistochemically determined ABCB5 protein expression (mean  SEM) by MCC xenografts (n ¼ 6e8, respectively) harvested 40 days after inoculation
to NSG mice, in experimental groups as in (a). Representative images of ABCB5 immunohistochemistry are shown on the left. Size bars ¼ 50 mm (NS: not
significant, *P < 0.05, **P < 0.01, ***P < 0.001, as determined by two-way ANOVA followed by the Bonferroni correction (a) or by the unpaired Student’s t-test
(b, c)). ABCB5, ATP-binding cassette member B5; ANOVA, analysis of variance; MCC, Merkel cell carcinoma; NSG, non-obese diabetic/severely combined
immunodeficiency IL-2Rg/; RT-PCR, reverse transcription polymerase chain reaction; SD, standard deviation; SEM, standard error of the mean.
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moderate apoptotic cell death compared with vehicle con-
trols (determined by cleaved caspase 3 immunostaining,
Figure 5b), the combination therapies involving carboplatin
or etoposide plus anti-ABCB5 mAb resulted in enhanced
MCC apoptosis, in tumor areas that also showed binding of
anti-ABCB5 mAb to MCC cells (Figure 5b). Without con-
current administration of carboplatin or etoposide, anti-
ABCB5 mAb administration to MKL-1 or WaGa tumor
xenograft-bearing NSG mice at the equivalent observation
endpoint did neither result in significant differences in tumor
growth (Supplementary Figure S4a online) nor in changes in
apoptotic tumor target cell death, compared with isotype
control mAb treatment alone (Supplementary Figure S4b).
In this study, on the basis of previously established roles of
ABCB5 as a clinically relevant chemoresistance mechanism
in cutaneous melanoma (Chartrain et al., 2012; Frank et al.,
2005; Wilson et al., 2014) and other cancers (Cheung
et al., 2011; Wilson et al., 2011), we analyzed ABCB5
expression and function in MCC, through the study of MCC
tumor biospecimens (n ¼ 85) obtained from 66 patients,
healthy human skin specimens from 10 individuals, and 4
established MCC cell lines. Our results provide evidence that
ABCB5 is highly expressed in MCC and that its expression
levels markedly surpass those in healthy human skin.
Importantly, we show that ABCB5 identifies carboplatin- and
etoposide-resistant MCC subsets in vitro and in tumor xeno-
grafts and clinical specimens in vivo. Additional ABC
transporters, namely ABCB1 and ABCC3, were also overex-
pressed in carboplatin- and etoposide-resistant compared to
wild-type MCC cell lines, raising the possibility of multiple
ABC transporter involvement in MCC chemoresistance.
Moreover, we cannot exclude the possibility that more pro-
nounced cellular quiescence in chemorefractory MCC cells
may have contributed to resistance to the agents used.
Although ABCB5 may function as an MCC efflux transporter,
as evidenced by our findings of ABCB5 mAb-mediated MCC
cell retention of the ATP transporter substrate rhodamine 123,
the question of whether ABCB5 directly effluxes the standard-
of-care clinical MCC therapeutic agents, carboplatin and
etoposide, as a mechanism of resistance, or if alternative,
efflux-independent ABCB5 functions (Ksander et al., 2014;
Wilson et al., 2014) might be primarily responsible for
MCC chemoresistance, requires further investigation.
The finding that ABCB5 serves as a chemoresistance
mediator in MCC is of potential high clinical significance,
because the emergence of resistance to first-line chemo-
therapy is a major impediment to successful MCC treat-
ment (Eng et al., 2007; Tai et al., 2000). Indeed, because
the addition of an ABCB5 blocking mAb to carboplatin
or etoposide treatment resulted in enhanced tumor cell
apoptosis and significant inhibition of tumor xenograft
growth, our results establish initial proof-of-principle that
ABCB5 can be targeted in MCC to attenuate resistance
to clinically relevant chemotherapeutic agents. In summary,
Figure 5. Effect of ABCB5 blockade on MCC tumor xenograft growth and chemotherapy-induced cytotoxicity. (a) Tumor growth kinetics (mean  SD)
and (b) ABCB5, secondary antibody (sec. anti-mIg staining, recognizing in vivo-administered anti-ABCB5 antibody) and cleaved caspase 3 (CC3)
immunohistochemical staining of MKL-1 (top, n ¼ 6e8) and WaGa (bottom, n ¼ 8e9) xenografts dissected from vehicle control-, carboplatin- (30 mg/kg/d), or
etoposide-treated (5 mg/kg/d) NSG mice also treated with anti-human ABCB5- or isotype control antibody (500 mg/d), respectively. Arrows in panel (a) indicate
days of carboplatin or etoposide and isotype control or anti-ABCB5 antibody administration. Size bars ¼ 50 mm (*P < 0.05, **P < 0.01, ***P < 0.001, as
determined by two-way ANOVA followed by the Bonferroni correction). ABCB5, ATP-binding cassette member B5; ANOVA, analysis of variance; MCC, Merkel
cell carcinoma; NSG, non-obese diabetic/severely combined immunodeficiency IL-2Rg/; SD, standard deviation.
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our findings provide a clear rationale to translate ABCB5-
targeted chemoresistance reversal strategies to the clinic
to enhance the efficacy of currently available systemic
MCC therapies.
MATERIALS AND METHODS
Clinical specimens, MCC cell lines, culture methods, and
generation of drug-resistant MCC lines
MCC biospecimens and healthy human skin were obtained from
patients and healthy volunteers in accordance with protocols
approved by the institutional review boards of Partners Health Care
Research Management and the Dana-Farber Cancer Institute and
assurances filed with and approved by the US Department of Health
and Human Services. Written informed consent was obtained from
all subjects. Authenticated human MCC cell lines were obtained
from Dr. James DeCaprio of the Dana-Farber Cancer Institute, Bos-
ton, MA (Rodig et al., 2012) and were cultured fewer than 6 months
in Roswell Park Memorial Institute 1640 medium supplemented with
20% (v/v) fetal bovine serum and 1% (v/v) penicillin/streptomycin
(Gibco, Life Technologies, Grand Island, NY). MCC cell lines were
rendered drug resistant to carboplatin or etoposide by incubation in
increasing doses of up to 150 mM carboplatin or of up to 3 mM
etoposide over the course of 2 months, respectively.
RNA extraction, RT-PCR, and real-time quantitative PCR
Human ABCB5 was amplified and sequenced after reverse tran-
scription of total RNA using ABCB5-specific primer pairs. Relative
ABCB5, ABCB1, ABCC3, and ABCG2 transcript levels were deter-
mined by real-time quantitative RT-PCR and calculated using the
2(DDCt) method (Schatton et al., 2008, 2010). See Supplementary
Materials online for primer sequences.
Immunohistochemistry and immunofluorescence staining
Immunofluorescence labeling for ABCB5 in cytospin preparations
of MCC cell lines, conventional histology, and immunohistochemical
analysis ofABCB5, cytokeratin 20, and/or cleavedcaspase 3 expression
by tumor biospecimens obtained from patients with MCC or human
MCC tumor xenografts, andof invivo anti-ABCB5mAbbinding toMCC
tumor xenograft tissue were carried out as described (Schatton et al.,
2008, 2010). ABCB5 immunoreactivity was quantified using ImageJ
software analysis, as described previously (Wilson et al., 2011).
Flow cytometry and cell viability measurements
ABCB5 surface protein expression by established wild-type, drug-
exposed, or drug-resistant MCC lines with or without concurrent
counterstaining with the viability dye, calcein acetoxymethyl ester,
was analyzed by single- or dual-color flow cytometry (Schatton
et al., 2008, 2010). Assessment of cell viability in anti-ABCB5
versus isotype control mAb-treated MCC cells was carried out by
annexin V/7-amino-actinomycin D staining and subsequent flow
cytometric analysis, as described (Schatton et al., 2010).
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) cytotoxicity assays
To confirm preferential chemosensitivity of wild-type versus drug-
resistant MCC lines and determine the effect of ABCB5 mAb
blockade on carboplatin- or etoposide-induced cell killing, MCC
cells were exposed to a range of concentrations of carboplatin or
etoposide in the presence or absence of anti-ABCB5 mAb or isotype
control mAb over a course of 7 days. Subsequently, in vitro growth
kinetics of cells were assayed using the TACS 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay
kit (Trevigen, Gaithersburg, MD).
Rhodamine 123 efflux transport assays
Efflux transport capacity for the green fluorescent dye, rhodamine
123, was assessed by flow cytometry for MCC cells incubated for
120 minutes at 37 C with the 3C2-1D12 anti-ABCB5 blocking mAb
(Frank et al., 2003, 2005; Ksander et al., 2014; Lin et al., 2013;
Schatton et al., 2008; Wilson et al., 2011) versus isotype control
mAb, as described previously (Frank et al., 2003; Lin et al., 2013).
Human MCC xenotransplantation, in vivo carboplatin and
etoposide treatment, and anti-ABCB5 mAb targeting
NSG mice were maintained and experiments performed in accor-
dance with IACUC-approved experimental protocols. For tumorige-
nicity studies,MCC cells were injected subcutaneously (1 107 cells/
inoculum) into the flanks of recipient NSG mice (Schatton et al.,
2008). At day 34 after tumor cell inoculation, mice were random-
ized to carboplatin, etoposide or vehicle control treatment groups and
carboplatin (75 mg/kg) or etoposide (10 mg/kg) were administered
daily by intraperitoneal injection for 6 consecutive days, as previously
described (Fichtner et al., 2008). Control animalswere givenvehicle at
equal volumes. For in vivoABCB5 targeting experiments, humanMCC
cells were grafted, mice randomized to experimental treatment
groups, and animals were injected intraperitoneally with anti-ABCB5
mAb or control mAb daily (500 mg per injection, respectively) for 9
consecutive days with or without concurrent administration of car-
boplatin (30 mg/kg) or etoposide (5 mg/kg) for 6 consecutive days
starting 72 hours after initial antibody treatment, respectively. Tumor
volumes were measured daily for the duration of the treatment and
tumor volumes were calculated as described (Schatton et al., 2008).
Statistics
Analyses were performed using the PRISM software (version 5 for
Macintosh, GraphPad Software, La Jolla, CA) and R version 3.02.
Statistical hypotheses were tested using the two-tailed Student’s
t-test, the nonparametric Mann-Whitney test, or two-way analysis of
variance (ANOVA) followed by the Bonferroni correction. Data were
tested for normal distribution using the D’Agostino and Pearson
omnibus normality test. A two-sided value of P < 0.05 was
considered statistically significant.
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